In recent years, GLP-1 RA has demonstrated several cardio-renal benefits in multiple preclinical and clinical models, including obesity, inflammation, and cardiovascular diseases, even in non-diabetic conditions [4]. This evidence concerns the gene GCG and obesity disorder.